Hairy Cell Leukemia Epidemiology Forecast

DelveInsight's 'Hairy Cell Leukemia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hairy Cell Leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Hairy Cell Leukemia Understanding

The DelveInsight Hairy Cell Leukemia epidemiology report gives a thorough understanding of the Hairy Cell Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hairy Cell Leukemia in the US, Europe, and Japan. The report covers the detailed information of the Hairy Cell Leukemia epidemiology scenario in seven major countries (US, EU5, and Japan).

Hairy Cell Leukemia Epidemiology Perspective by DelveInsight

The Hairy Cell Leukemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Hairy Cell Leukemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Hairy Cell Leukemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hairy Cell Leukemia Detailed Epidemiology Segmentation

The Hairy Cell Leukemia epidemiology covered in the report provides historical as well as forecasted Hairy Cell Leukemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


The DelveInsight Hairy Cell Leukemia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Hairy Cell Leukemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Hairy Cell Leukemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Hairy Cell Leukemia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Hairy Cell Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hairy Cell Leukemia
  • The report provides the segmentation of the Hairy Cell Leukemia epidemiology

Report Highlights

  • 11-Year Forecast of Hairy Cell Leukemia epidemiology
  • 7MM Coverage
  • Total Cases of Hairy Cell Leukemia
  • Total Cases of Hairy Cell Leukemia according to segmentation
  • Diagnosed cases of Hairy Cell Leukemia

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hairy Cell Leukemia?
  • What are the key findings pertaining to the Hairy Cell Leukemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Hairy Cell Leukemia across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Hairy Cell Leukemia?
  • What are the currently available treatments of Hairy Cell Leukemia?

Reasons to buy

The Hairy Cell Leukemia Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hairy Cell Leukemia market
  • Quantify patient populations in the global Hairy Cell Leukemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hairy Cell Leukemia therapeutics in each of the markets covered
  • Understand the magnitude of Hairy Cell Leukemia population by its epidemiology
  • The Hairy Cell Leukemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of HCL

3. Disease Background and Overview

3.1. Introduction

3.2. Symptoms

3.3. Risk Factor

3.4. Staging and Risk Stratification

3.5. Genetics

3.6. Morphologic and Immunophenotypic Features

3.7. Biology of HCL

3.8. Pathogenesis

3.9. Diagnosis

3.10. Differential Diagnosis

3.11. Diagnostic Guidelines

3.11.1. NCCN Clinical Practice Guidelines in Oncology - Hairy Cell Leukemia, Version 2.2018

3.11.2. European Society for Medical Oncology (ESMO): Clinical Practice Guidelines - Hairy Cell Leukemia

3.11.3. Consensus guidelines for the diagnosis Classic Hairy Cell Leukemia

4. Epidemiology and Patient Population

4.1. Key Findings

5. 7MM Epidemiology

5.1. Assumptions and rationale

5.2. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM

5.3. The United States

5.3.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United States

5.3.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the United States

5.3.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in the United States

5.3.4. Gender-Specific cases of Hairy Cell Leukemia (HCL) in the United States

5.4. EU5 Countries

5.4.1. Germany

5.4.1.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany

5.4.1.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany

5.4.1.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany

5.4.1.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany

5.4.2. France

5.4.2.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France

5.4.2.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France

5.4.2.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in France

5.4.2.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in France

5.4.3. Italy

5.4.3.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy

5.4.3.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy

5.4.3.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy

5.4.3.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy

5.4.4. Spain

5.4.4.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain

5.4.4.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Spain

5.4.4.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain

5.4.4.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain

5.4.5. United Kingdom

5.4.5.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United Kingdom

5.4.5.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the United Kingdom

5.4.5.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in the United Kingdom

5.4.5.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in the United Kingdom

5.5. Japan

5.5.1. Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan

5.5.2. Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Japan

5.5.3. Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan

5.5.4. Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan

6. Treatment and Management

6.1. ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for Treatment

6.2. Consensus Guidelines for the management of patients with classic Hairy Cell Leukemia

6.3. NCCN Clinical Practice Guidelines Hairy Cell Leukemia, Version 1.2021

6.4. Treatment Options

6.5. Treatment Guidelines

7. Unmet Needs

8. Organizations contributing toward HCL

9. Case studies

9.1. A Case Report of Hairy Cell Leukemia Presenting Concomitantly with Sweet Syndrome

9.2. Skin Metastasis in Patient with Hairy Cell Leukemia: Case Report

9.3. Tuberculous Meningoencephalitis in a Patient with Hairy Cell Leukemia in Complete Remission

9.4. A Case Report of CD27-positive hairy cell leukemia-Japanese variant

10. KOL Views

11. Patient Journey

12. Appendix

12.1. Report Methodology

12.2. References

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Table

Table 1: Summary of Hairy Cell Leukemia Market, Epidemiology, and Key Events (2017–2030)

Table 2: Genomic alterations in hairy cell leukemia (HCL), hairy cell leukemia‐variant (HCL‐V), splenic diffuse red pulp lymphoma (SDRPL) and splenic marginal zone lymphoma (SMZL)

Table 3: NCCN Categories of Evidence and Consensus

Table 4:  Diagnosis and workup for HCL by NCCN

Table 5: Diagnostic workup of classical HCL

Table 6: Diagnostic criteria for HCL and HCL-V

Table 7: Initial workup for a patient suspected of hairy cell leukemia

Table 8: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM (2017–2030)

Table 9: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United States (2017–2030)

Table 10: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Table 11: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the US (2017–2030)

Table 12: Gender-specific cases of Hairy Cell Leukemia (HCL) in the US (2017–2030)

Table 13: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Table 14: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany (2017–2030)

Table 15: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany (2017–2030)

Table 16: Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Table 17:  Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Table 18: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France (2017–2030)

Table 19: Age-specific Diagnosed Incident of Hairy Cell Leukemia in France (2017–2030)

Table 20: Gender-specific cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Table 21: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Table 22: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy (2017–2030)

Table 23: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy (2017–2030)

Table 24: Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Table 25: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Table 26: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Table 27: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain (2017–2030)

Table 28: Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Table 29: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the United Kingdom (2017–2030)

Table 30: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Table 31: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the UK (2017–2030)

Table 32: Gender-specific cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Table 33: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Table 34: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Table 35: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan (2017–2030)

Table 36: Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Table 37: Definition of response categories

Table 38: Initial workup for a patient suspected of hairy cell leukemia

Table 39: Implications for Recommendations

Table 40: Assessment of response in HCL

Table 41: Assessment of response in HCL

Table 42: Supportive Care

List of Figures

Figure 1: RAF-MEK-ERK signaling pathway in hairy cell leukemia

Figure 2: B-cell development in peripheral lymphoid organs: the germinal center reaction

Figure 3: Signaling pathways involved in hairy-cell leukemia (HCL) growth

Figure 4: Hairy-cell leukemia (HCL) homing and dissemination properties

Figure 5: Bone-marrow fibrosis in hairy-cell leukemia (HCL)

Figure 6: ‘Hairy’ morphology: molecular mediators and their relationship with hairy-cell survival

Figure 7:  Histologic image of a hairy cell

Figure 8: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in 7MM (2017–2030)

Figure 9: Total Diagnosed Incident Cases of HCL in the United States (2017–2030)

Figure 10: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the US (2017–2030)

Figure 11: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the US (2017–2030)

Figure 12: Gender-Specific cases of Hairy Cell Leukemia (HCL) in the US (2017–2030)

Figure 13: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Figure 14: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Germany (2017–2030)

Figure 15: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Germany (2017–2030)

Figure 16: Gender-specific cases of Hairy Cell Leukemia (HCL) in Germany (2017–2030)

Figure 17: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Figure 18: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in France (2017–2030)

Figure 19: Age-specific Diagnosed Incident of Hairy Cell Leukemia in France (2017–2030)

Figure 20: Gender-specific cases of Hairy Cell Leukemia (HCL) in France (2017–2030)

Figure 21: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Figure 22: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Italy (2017–2030)

Figure 23: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Italy (2017–2030)

Figure 24: Gender-specific cases of Hairy Cell Leukemia (HCL) in Italy (2017–2030)

Figure 25: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Figure 26: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Spain (2017–2030)

Figure 27: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Spain (2017–2030)

Figure 28: Gender-specific cases of Hairy Cell Leukemia (HCL) in Spain (2017–2030)

Figure 29: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Figure 30: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in the UK (2017–2030)

Figure 31: Age-specific Diagnosed Incident of Hairy Cell Leukemia in the UK (2017–2030)

Figure 32: Gender-specific cases of Hairy Cell Leukemia (HCL) in the UK (2017–2030)

Figure 33: Total Diagnosed Incident Cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Figure 34: Diagnosed Incident of Hairy Cell Leukemia by Symptoms in Japan (2017–2030)

Figure 35: Age-specific Diagnosed Incident of Hairy Cell Leukemia in Japan (2017–2030)

Figure 36: Gender-specific cases of Hairy Cell Leukemia (HCL) in Japan (2017–2030)

Figure 37: Treatment Algorithm

Figure 38: Treatment algorithm for relapsed and refractory classical HCL according to ESMO guidelines

Figure 39: Treatment algorithm according to ESMO guidelines

Figure 40: Treatment algorithm according to ESMO guidelines

Figure 41: NCCN Treatment Guidelines

Figure 42: Unmet Needs

  • Tags:
  • Hairy Cell Leukemia Epidemiology
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Pipeline
  • Hairy Cell Leukemia Companies
  • Hairy Cell Leukemia prevalent popu...
  • Hairy Cell Leukemia incident popul...
  • Hairy Cell Leukemia patients diagn...
  • Hairy Cell Leukemia treatment algo...

Forward to Friend

Need A Quote